Mr. Karavetsos will step down Jan. 20 — the same day President-elect Donald Trump will be sworn in as president.
While an FDA spokeswoman confirmed the departure, she declined to share any additional information or say whether the two events are related.
Mr. Karavetsos has served as head of the OCI since January 2015. The office conducts criminal investigations into allegations surrounding food, drugs, medical devices, cosmetics and tobacco.
More articles on supply chain:
FDA approves Allergan’s breast implant
Red Cross issues emergency call for blood donations amid winter shortage
Descartes Systems acquires logistics trade data provider for $52.7M
